DHX15 and myelodysplastic syndrome: RNAi‐mediated DHX15 suppression inhibited the proliferation of MCF‐7 and T47D human breast cancer cells.19 The DHX15 p.R222G mutation has been identified in de novo or relapsed acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients and has been implicated as a potential new AML driver gene.20, 21, 22, 23 Using real‐time qRT‐PCR and Western blotting, we observed higher DHX15 mRNA and protein levels, respectively, in human ALL samples than in normal bone marrow (BM) cells.